@article{e723d08d123e4483a21d851bebb19b8e,
title = "The transfer of pravastatin in the dually perfused human placenta",
abstract = "HMG-CoA reductase inhibitors (statins) are contraindicated during pregnancy. However, it has been suggested that the hydrophilic property of pravastatin prevents its placental transfer to the fetus, explaining neutral effects observed in controlled studies. Using the ex-vivo placental perfusion model, placental transfer of pravastatin (50 ng/ml) was determined. The mean maximum fetal concentration was 4.4 ng/ml. The transfer of pravastatin's across the placenta appears to be limited and slow. Combined with its rapid elimination half-life of 2 h and 50% protein binding, the transfer of pravastatin from maternal to fetal compartments is substantially more limited than observed in the perfusion experiments.",
keywords = "Cholesterol, Placental perfusion, Pravastatin, Pregnancy, Teratogenic",
author = "J. Zarek and DeGorter, {M. K.} and A. Lubetsky and Kim, {R. B.} and Laskin, {C. A.} and H. Berger and G. Koren",
note = "Funding Information: The authors would like to thank the dedicated staff at St. Michael's Hospital for facilitating placentae collection. This study was approved by St. Michael's Hospital research ethics board and is supported by the Canadian Institutes for Health Research and the Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation (Sickkids Hospital). GK is the holder of the Ivey Chair in Molecular Toxicology, The Department of Medicine, University of Western Ontario.",
year = "2013",
month = aug,
doi = "10.1016/j.placenta.2013.05.002",
language = "אנגלית",
volume = "34",
pages = "719--721",
journal = "Placenta",
issn = "0143-4004",
publisher = "W.B. Saunders Ltd",
number = "8",
}